scholarly journals Eukaryotic initiation factor 4 gamma 2 contributes to neuropathic pain through downregulation of Kv1.2 and the mu opioid receptor in mouse primary sensory neurones

Author(s):  
Zhen Zhang ◽  
Bixin Zheng ◽  
Shibin Du ◽  
Guang Han ◽  
Hui Zhao ◽  
...  
Pain ◽  
2008 ◽  
Vol 138 (2) ◽  
pp. 318-329 ◽  
Author(s):  
Yun Guan ◽  
Lisa M. Johanek ◽  
Timothy V. Hartke ◽  
Beom Shim ◽  
Yuan-Xiang Tao ◽  
...  

Pain ◽  
2017 ◽  
Vol 158 (12) ◽  
pp. 2431-2441 ◽  
Author(s):  
Cristina D. Peterson ◽  
Kelley F. Kitto ◽  
Eyup Akgün ◽  
Mary M. Lunzer ◽  
Maureen S. Riedl ◽  
...  

1997 ◽  
Vol 87 (5) ◽  
pp. 1127-1138 ◽  
Author(s):  
Elizabeth K. Gies ◽  
Dawn M. Peters ◽  
Carol R. Gelb ◽  
Kathleen M. Knag ◽  
Robert A. Peterfreund

Background The mu opioid receptor (MuOR) is a member of the superfamily of G protein-coupled receptors that mediates the analgesic actions of endogenous opioid peptides and the narcotic alkaloid derivatives of morphine. Activation and translocation of protein kinase C (PKC) by N-methyl-D-aspartate receptor stimulation correlates with resistance to opioid drugs in experimental states of neuropathic pain, but the cellular mechanisms of resistance have not been identified. One possibility is that PKC activation regulates MuOR mRNA expression and thus the ability to generate functional receptors. Using a human neuroblastoma cell line, the authors tested the hypothesis that phorbol ester activation of PKC regulates MuOR mRNA levels. Methods SH-SY5Y cells were maintained in a continuous monolayer culture and treated with phorbol esters or other agents before extraction of total cellular RNA. Slot-blot hybridization was used to measure the level of MuOR mRNA using 32P-labeled MuOR cDNA probes under high-stringency conditions. Autoradiograms were analyzed by scanning and densitometry. Results MuOR mRNA levels decreased in a dose- and time-dependent manner after tetradecanoyl phorbol acetate (TPA) was administered to activate PKC. The nadir, a level of approximately 50% of control, was at 2-8 h, followed by gradual recovery. The actions of TPA were blocked by pretreatment with the selective PKC inhibitor bisindolylmaleimide, but not by inhibition of protein synthesis with cycloheximide or anisomycin. The combination of TPA treatment and transcription inhibition with actinomycin D was associated with a transient increase in MuOR mRNA. Conclusions Mu opioid receptor mRNA levels are regulated by activation of PKC in a neuronal model. Protein kinase C effects which decrease MuOR mRNA levels appear largely independent of new protein synthesis, and cytotoxicity does not account for the findings. Plasticity of MuOR gene expression may contribute to variations in clinical responses to opioid analgesics in clinical states such as neuropathic pain.


2008 ◽  
Vol 33 (10) ◽  
pp. 2134-2141 ◽  
Author(s):  
Jun-Yang Wang ◽  
Mei Zhao ◽  
Fen-Sheng Huang ◽  
Jing-Shi Tang ◽  
Yu-Kang Yuan

2015 ◽  
Vol 58 (21) ◽  
pp. 8647-8657 ◽  
Author(s):  
Eyup Akgün ◽  
Muhammad I. Javed ◽  
Mary M. Lunzer ◽  
Michael D. Powers ◽  
Yuk Y. Sham ◽  
...  

2020 ◽  
Vol 16 ◽  
pp. 174480692096614
Author(s):  
Linlin Wang ◽  
Kesai Hou ◽  
Hongbo Wang ◽  
Fenghua Fu ◽  
Longchuan Yu

Lots of studies have demonstrated that anterior cingulate cortex plays important roles in the pain perception and pain modulation. The present study explored the role of mu-opioid receptor in nociceptive modulation in anterior cingulate cortex of rats with neuropathic pain. Neuropathic pain model was set up by chronic constriction injury of the left sciatic nerve of rats. The hindpaw withdrawal latency to thermal and mechanical stimulation, by hot plate and Randall Selitto Test respectively, was used to evaluate the rat’s responses to noxious stimulation. Results showed that intra-anterior cingulate cortex injection of morphine could induce the antinociception dose-dependently. By intra-anterior cingulate cortex injection of opioid receptor antagonist, the morphine-induced antinociception could be attenuated by naloxone, as well as much significantly by the selective mu-opioid receptor antagonist β-funaltrexamine, indicating that mu-opioid receptor is involved in the morphine-induced antinociception in anterior cingulate cortex of rats with neuropathic pain. The morphine-induced antinociception was much more decreased in rats with neuropathic pain than that in normal rats, and there was a significant decrease in mu-opioid receptor messenger RNA levels in anterior cingulate cortex of rats with neuropathic pain, indicating that there may be a down-regulation in mu-opioid receptor expression in anterior cingulate cortex of rats with neuropathic pain. To further confirm the role of mu-opioid receptor in morphine-induced antinociception in anterior cingulate cortex, normal rats were received intra-anterior cingulate cortex administration of small interfering RNA targeting mu-opioid receptor and it was found that there was a down-regulation in mu-opioid receptor messenger RNA levels, as well as a down-regulation in mu-opioid receptor expression in anterior cingulate cortex tested by real-time polymerase chain reaction and western blotting. Furthermore, the morphine-induced antinociceptive effect decreased significantly in rats with small interfering RNA targeting mu-opioid receptor, which indicated that knockdown mu-opioid receptor in anterior cingulate cortex could also attenuate morphine-induced antinociceptive effect. These results strongly suggest that mu-opioid receptor plays a significant role in nociceptive modulation in anterior cingulate cortex of rats.


Sign in / Sign up

Export Citation Format

Share Document